Cladribine

Drug Profile

Cladribine

Alternative Names: 2-CdA; 2-Chloro-2-deoxyadenosine; 2-Chlorodeoxyadenosine; 2CDA; Chlorodeoxyadenosine; Intocel; Leustat; Leustatin; Leustatine; Mavenclad; Movectro; Mylinax; N-l-Leucyl-doxorubicin; RWJ 26251

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scripps Clinic
  • Developer EMD Serono; Janssen-Cilag; Merck Serono; Orphan Australia
  • Class Antineoplastics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis; Leukaemia; Lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Hairy cell leukaemia; Leukaemia; Lymphoma; Multiple sclerosis
  • No development reported Psoriasis; Transplant rejection

Most Recent Events

  • 05 Sep 2017 Additional efficacy and adverse events data from the phase III CLARITY Extension trial in Multiple sclerosis released by Merck
  • 05 Sep 2017 Efficacy and adverse events data from the phase III CLARITY Extension trial in Multiple sclerosis released by Merck
  • 25 Aug 2017 Merck plans to file regulatory approvals in other countries including the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top